Enfusion Stock Today

ENFN Stock  USD 9.20  0.05  0.54%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Less than 1

 
High
 
Low
Very Small
Enfusion is selling at 9.20 as of the 23rd of July 2024; that is 0.54 percent decrease since the beginning of the trading day. The stock's open price was 9.25. Enfusion has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Enfusion are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of June 2024 and ending today, the 23rd of July 2024. Click here to learn more.
Business Domain
Software & Services
IPO Date
21st of October 2021
Category
Technology
Classification
Information Technology
Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. Enfusion Inc. was incorporated in 2021 and is headquartered in Chicago, Illinois. Enfusion Inc operates under SoftwareApplication classification in the United States and is traded on New York Stock Exchange. The company has 91.91 M outstanding shares of which 1.95 M shares are currently shorted by private and institutional investors with about 4.61 trading days to cover. More on Enfusion

Moving together with Enfusion Stock

  0.78U Unity SoftwarePairCorr
  0.73BL BlacklinePairCorr

Moving against Enfusion Stock

  0.62VERX VertexPairCorr
  0.6AI C3 Ai IncPairCorr
  0.57DPSI DecisionPoint SystemsPairCorr
  0.5PD PagerdutyPairCorr
  0.45VS Versus SystemsPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Enfusion Stock Highlights

ESG Sustainability
Environmental
Governance
Social
Business ConcentrationApplication Software, Software - Application, Information Technology, NYSE Composite, Information Technology, Software, Software—Application, Technology (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover1.861.6016
Fairly Up
Slightly volatile
Gross Profit Margin0.770.6697
Fairly Up
Very volatile
Total Current Liabilities14.2 M20.3 M
Way Down
Slightly volatile
Non Current Liabilities Total10.6 M11.2 M
Notably Down
Slightly volatile
Total Assets88.2 M109 M
Significantly Down
Slightly volatile
Total Current Assets66.3 M69.9 M
Notably Down
Slightly volatile
Debt Levels
Enfusion can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Enfusion's financial leverage. It provides some insight into what part of Enfusion's total assets is financed by creditors.
Liquidity
Enfusion currently holds 15.44 M in liabilities. Enfusion has a current ratio of 8.99, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Enfusion's use of debt, we should always consider it together with its cash and equity.

Change In Working Capital

(9.91 Million)
Enfusion (ENFN) is traded on New York Stock Exchange in USA. It is located in 125 South Clark Street, Chicago, IL, United States, 60603 and employs 1,102 people. Enfusion is listed under Application Software category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 850.18 M. Enfusion conducts business under Software sector and is part of Information Technology industry. The entity has 91.91 M outstanding shares of which 1.95 M shares are currently shorted by private and institutional investors with about 4.61 trading days to cover. Enfusion currently holds about 56.56 M in cash with 24.48 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.84.
Check Enfusion Probability Of Bankruptcy
Ownership Allocation
The majority of Enfusion outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Enfusion to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Enfusion. Please pay attention to any change in the institutional holdings of Enfusion as this could imply that something significant has changed or is about to change at the company. Also note that almost three million six hundred seventy-six thousand four hundred fifty-six invesors are currently shorting Enfusion expressing very little confidence in its future performance.
Check Enfusion Ownership Details

Enfusion Stock Institutional Holders

InstituionRecorded OnShares
Lead Edge Capital Management, Llc2024-03-31
851 K
Geode Capital Management, Llc2024-03-31
815.1 K
Wasatch Advisors Lp2024-03-31
792.1 K
State Street Corporation2024-03-31
755.7 K
Bank Of America Corp2024-03-31
745.5 K
Wellington Management Company Llp2024-03-31
733.1 K
Scalar Gauge Management, Llc2024-03-31
503.5 K
Next Century Growth Investors Llc2024-03-31
467.3 K
Northern Trust Corp2024-03-31
352.9 K
Iconiq Capital, Llc2024-03-31
14 M
Brown Capital Management, Llc2024-03-31
10 M
View Enfusion Diagnostics

Enfusion Historical Income Statement

At this time, Enfusion's Net Income From Continuing Ops is very stable compared to the past year. As of the 23rd of July 2024, EBIT is likely to grow to about 12.5 M, while Tax Provision is likely to drop about 867 K. View More Fundamentals

Enfusion Stock Against Markets

Enfusion Corporate Management

Stephen DortonChief OfficerProfile
Michael BerryChief OfficerProfile
Lorelei SkillmanChief OfficerProfile
Stephen MalherbeManaging PartnerProfile
Oleg MovchanInterim DirectorProfile
Bronwen BastoneChief OfficerProfile
Joseph DefeoGlobal ProductionProfile

Additional Information and Resources on Investing in Enfusion Stock

When determining whether Enfusion offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enfusion's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enfusion Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enfusion Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enfusion. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census.
To learn how to invest in Enfusion Stock, please use our How to Invest in Enfusion guide.
You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Application Software space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enfusion. If investors know Enfusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enfusion listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.94)
Earnings Share
0.02
Revenue Per Share
2.055
Quarterly Revenue Growth
0.173
Return On Assets
0.0331
The market value of Enfusion is measured differently than its book value, which is the value of Enfusion that is recorded on the company's balance sheet. Investors also form their own opinion of Enfusion's value that differs from its market value or its book value, called intrinsic value, which is Enfusion's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enfusion's market value can be influenced by many factors that don't directly affect Enfusion's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enfusion's value and its price as these two are different measures arrived at by different means. Investors typically determine if Enfusion is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enfusion's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.